Evidence map›Paper›PMID 41507463›Full record

ArticleEMBO molecular medicine2026

Functional rescue and AI analysis of a human inactivating GPCR mutation using a small molecule.

Debajyoti Das, Amanda Wyatt, Sarath Sivaprasad, Vanessa Wahl, Sen Qiao, Fabien Ectors, Zulfiah M Moosa, Claire L Newton, Mario Fritz, Robert P Millar and 1 more

Abstract read
In one paragraph

Article in EMBO molecular medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Debajyoti DasDepartment of Pharmacology, Center for Molecular Signaling (PZMS), Center for Gender-Specific Biology and Medicine (CGBM), Saarland University School of Medicine, 66421, Homburg, Germany.ORCID 0009-0006-8238-7529
Amanda WyattDepartment of Pharmacology, Center for Molecular Signaling (PZMS), Center for Gender-Specific Biology and Medicine (CGBM), Saarland University School of Medicine, 66421, Homburg, Germany.ORCID 0000-0003-1107-3857
Sarath SivaprasadCISPA Helmholtz Center for Information Security, 66123, Saarbrücken, Germany.
Vanessa WahlDepartment of Pharmacology, Center for Molecular Signaling (PZMS), Center for Gender-Specific Biology and Medicine (CGBM), Saarland University School of Medicine, 66421, Homburg, Germany.ORCID 0000-0002-0070-3465
Sen QiaoDepartment of Pharmacology, Center for Molecular Signaling (PZMS), Center for Gender-Specific Biology and Medicine (CGBM), Saarland University School of Medicine, 66421, Homburg, Germany.
Fabien EctorsFARAH Mammalian Transgenics Platform, Liège University, 4000, Liège, Belgium.ORCID 0000-0003-2846-7019
Zulfiah M MoosaCentre for Neuroendocrinology, Department of Immunology, Faculty of Health Sciences, University of Pretoria, 0084, Pretoria, South Africa.
Claire L NewtonCentre for Neuroendocrinology, Department of Immunology, Faculty of Health Sciences, University of Pretoria, 0084, Pretoria, South Africa.ORCID 0000-0001-6050-556X
Mario FritzCISPA Helmholtz Center for Information Security, 66123, Saarbrücken, Germany.
Robert P MillarCentre for Neuroendocrinology, Department of Immunology, Faculty of Health Sciences, University of Pretoria, 0084, Pretoria, South Africa. bob.millar@up.ac.za.ORCID 0000-0003-3606-2708
Ulrich BoehmDepartment of Pharmacology, Center for Molecular Signaling (PZMS), Center for Gender-Specific Biology and Medicine (CGBM), Saarland University School of Medicine, 66421, Homburg, Germany. ulrich.boehm@uks.eu.ORCID 0000-0003-2436-6907

Funding

COST action BM1105Deutsche Forschungsgemeinschaft (DFG) SFB 894Deutsche Forschungsgemeinschaft (DFG) SFB/TR 152South African National Research Foundation (NRF) 94008Wellcome Trust 105824
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) carry out the majority of cellular transmembrane signaling. Many pathologies have underlying GPCR mutations, most of which cause misfolding and GPCR cell surface trafficking failure. Large libraries of existing small molecule GPCR ligands could be repurposed as pharmacological chaperones (PCs) which restore mutant GPCR folding and function, presenting an exciting alternative to complex gene repair, yet such in vivo studies are limited. Therefore, as proof-of-concept, we use one such known ligand/PC, Org42599/Org43553, to show functional rescue in mice bearing an inactivating human luteinizing hormone receptor (LHR) mutation. Mutant males had delayed puberty and Leydig cell LHR signaling impairment, however, fertility was unaffected. Mutant females had irregular estrous cycles, anovulation, abrogated ovarian LHR signaling, and complete infertility. PC treatment of mutant females restored LH signaling and estrous cyclicity. To characterize treatment efficacy, we developed an AI algorithm that reliably identified inherent differences among experimental groups, enabling functional analysis of the treatment effect in vivo. Our data set the stage to integrate AI analysis with GPCR-targeting PC molecules to treat diverse GPCR-based diseases.

Indexed as

MutationReceptors, G-Protein-CoupledReceptors, LHAnimalsFemaleHumansMaleMiceSignal TransductionReceptors, G-Protein-CoupledReceptors, LHAICalcium ImagingInactivating MutationLuteinizing Hormone ReceptorPharmacological Chaperone

Identifiers

PMID41507463
PMCPMC12905377

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.